AbbVie Filed Patent Suits To Delay Competition, Court Told

The patent lawsuits filed by AbbVie Inc. and Besins Healthcare Inc. over generic testosterone replacement treatments were “anti-competitive weapons” used to delay competition for the brand-name drug AndroGel, an attorney for the Federal Trade Commission said Wednesday while opening the bench trial in the agency’s antitrust suit in Pennsylvania federal court.

Those so-called weapons were sham litigation against Teva Pharmaceuticals USA Inc. and Perrigo Co. which reaped over $1 billion in ill-gotten monopoly profits for the brand-name drug makers, and deprived customers of lower-priced versions of...

Already a subscriber? Click here to view full article